In Depth 11 Aug 2022 Biosecurity is synthetic biology’s most crucial ally Synthetic biology has made it easier than ever to engineer organisms to serve our needs. But as the technology becomes widespread, concerns about its potential misuse arise. How can we ensure biosecurity without hindering the advance of synthetic biology? Biosecurity consists of the prevention of and response to the release of potentially harmful organisms. Now […] August 11, 2022 - 6 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Aro Biotherapeutics gets FDA orphan drug designation for treatment of Pompe Disease Aro Biotherapeutics says the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABX1100, an investigational Centyrin-siRNA conjugate that targets the Gys1 gene in the muscle, for the treatment of Pompe disease. “We are pleased to have received this designation and are gratified by the FDA’s recognition of the potential of ABX1100 […] August 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Stem cell therapy to be used in treatment of long COVID by Panacell Biotech A South Korean biotech company says it will use natural killer (NK) cells, exosomes and brown adipose-derived stem cells (ADSC) as treatment of long COVID. NK cells are a type of immune cell that have granules or small particles that can kill tumor cells or those infected with a virus. Panacell Biotech said they can […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 GentiBio and Bristol Myers Squibb to develop engineered Treg therapies for inflammatory bowel diseases GentiBio, Inc. has entered into a collaboration with Bristol Myers Squibb to develop new engineered regulatory T cells (Treg) therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD). The collaboration brings together GentiBio’s engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers Squibb’s […] August 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 10 Aug 2022 How the UK precision breeding bill could unshackle gene editing The U.K. is considering lowering restrictions on gene-edited crops. PacBio’s Neil Ward explains how the changes could impact the gene editing landscape. CRISPR gene editing technology has changed the game in the biotech industry by making it easier than ever before to make small changes to the genome. In addition to myriad healthcare applications, the […] August 10, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Research discovery may help diagnose and treat cancer and brain disorders Researchers at Queen’s University Belfast in Northern Ireland have revealed how the pathway of an identified protein could lead to early diagnosis and targeted treatment for several cancers and brain disorders. The team of researchers discovered how the journey or molecular pathway of an identified protein is both essential for brain development and how an […] August 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Bone Therapeutics and Medsenic set to combine in share for share deal Subject to the outcome of a shareholders’ meeting, Bone Therapeutics and Medsenic are set to combine their operations reducing risks and broadening portfolios. The companies announced they have signed a share for share binding contribution today (August 10) which will create new enterprise BioSenic. Brussels and Paris-based Bone Therapeutics is a cell therapy company that […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Captor Therapeutics names lead candidate in fight against hepatocellular carcinoma A Polish biopharma company focused on treating cancer and autoimmune diseases announced today (August 10) that it has chosen a lead candidate for the treatment of hepatocellular carcinoma. The molecular glue candidate, CPT-6281 will be Captor Therapeutic’s CT-01 project which will initially focus on the clinical development of the asset as a targeted protein degradation […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Epilepsy drug accepted for review in Canada and Israel SK Biopharmaceuticals, Co., Ltd. says Health Canada has accepted Paladin Labs Inc.’s filing of a new drug submission (NDS) for cenobamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. If Health Canada approves the NDS, Paladin Labs would be able to […] August 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Asthma in the spotlight as Upstream Bio starts trial and UK universities propose new long-term treatment Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, has initiated a phase 1b multiple ascending dose study of UPB-101 in asthma patients with the dosing of the first patient. Meanwhile, a possible way to tackle one of the underlying causes of asthma has been developed by researchers from Aston University and […] August 9, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Relmada Therapeutics gets Fast Track designation for major depressive disorder treatment Relmada Therapeutics, Inc., a late-stage biotech company addressing diseases of the central nervous system (CNS), has been given U.S. Food and Drug Administration (FDA) Fast Track designation to REL-1017, the company’s novel NMDA receptor (NMDAR) channel blocker, as a monotherapy for the treatment of major depressive disorder (MDD). “The receipt of Fast Track Designation represents […] August 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Start-up receives science and business support at Lab Hotel Stevenage Bioscience Catalyst (SBC) has welcomed Inspira Pharmaceuticals to its Lab Hotel, a facility offering free lab and office accommodation for six months to start-ups. The start-ups receive scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop. Biotech start-up Rory McGoldrick, co-founder and CEO of […] August 9, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email